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ABSTRACT
Objectives: To determine the effectiveness of
collaborative care in reducing depression in primary
care patients with diabetes or heart disease using
practice nurses as case managers.
Design: A two-arm open randomised cluster trial with
wait-list control for 6 months. The intervention was
followed over 12 months.
Setting: Eleven Australian general practices, five
randomly allocated to the intervention and six to the
control.
Participants: 400 primary care patients (206
intervention, 194 control) with depression and type 2
diabetes, coronary heart disease or both.
Intervention: The practice nurse acted as a case
manager identifying depression, reviewing pathology
results, lifestyle risk factors and patient goals and
priorities. Usual care continued in the controls.
Main outcome measure: A five-point reduction in
depression scores for patients with moderate-to-severe
depression. Secondary outcome was improvements in
physiological measures.
Results: Mean depression scores after 6 months of
intervention for patients with moderate-to-severe
depression decreased by 5.7±1.3 compared with
4.3±1.2 in control, a significant (p=0.012) difference.
(The plus–minus is the 95% confidence range.)
Intervention practices demonstrated adherence to
treatment guidelines and intensification of treatment for
depression, where exercise increased by 19%, referrals
to exercise programmes by 16%, referrals to mental
health workers (MHWs) by 7% and visits to MHWs by
17%. Control-practice exercise did not change,
whereas referrals to exercise programmes dropped by
5% and visits to MHWs by 3%. Only referrals to MHW
increased by 12%. Intervention improvements were
sustained over 12 months, with a significant (p=0.015)
decrease in 10-year cardiovascular disease risk from
27.4±3.4% to 24.8±3.8%. A review of patients
indicated that the study’s safety protocols were
followed.
Conclusions: TrueBlue participants showed
significantly improved depression and treatment
intensification, sustained over 12 months of
intervention and reduced 10-year cardiovascular
disease risk. Collaborative care using practice nurses
appears to be an effective primary care intervention.
Trial registration: ACTRN12609000333213 (Australia
and New Zealand Clinical Trials Registry).
INTRODUCTION
Management of diabetes and heart disease
has been highlighted as one of the global
‘grand challenges in chronic non-
communicable diseases’1 because the preva-
lence of these two preventable diseases is
increasing.2 Along with depression, they have
been identified as health priority areas in
many countries. A vicious cycle exists
between depression and these chronic dis-
eases, with each being a risk factor for the
ARTICLE SUMMARY
Article focus
▪ To determine the effectiveness of a collaborative
care model to reduce depression in primary care
patients with diabetes or heart disease.
▪ To determine the effectiveness of using practice
nurses as case managers of patients with
depression and diabetes, heart disease or both.
Key messages
▪ The TrueBlue model of collaborative care can be
introduced within the general practice workforce
with practice nurses taking on the role of case
manager.
▪ Practice nurses can improve the care of depres-
sion in patients with diabetes or heart disease,
leading to better outcomes and reduced 10-year
cardiovascular disease risk.
▪ The care of patients using the TrueBlue model is
closer to ‘best practice’ guidelines, with substan-
tially better levels of adherence to guideline-
recommended checks than those occurring in
usual care.
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other.3 Higher mortality has been demonstrated for
people with depression and type 2 diabetes (T2DM) or
coronary heart disease (CHD) beyond that due to the
separate diseases alone.4 For patients with depression
and T2DM or CHD or both, there are increased risks of
adverse outcomes,5 but this comorbid depression is
often missed in primary care.6 Consequently, the identi-
fication of depression has now been incorporated into
many heart disease guidelines as one of the require-
ments for optimal management. Meeting these chal-
lenges will require an innovative use of the existing
general practice workforce, and such a reorientation of
resources has been identified as one of the grand
challenges.1
Collaborative care is a system that has been shown to be
more effective for chronic disease management than
standard care.7 It includes a reorientation of the medical
workforce through new or adjusted roles for team
members, particularly using practice nurses (PNs) as the
identified case manager to undertake the care of the
patients.8 9 It also includes the use of evidence-based
guidelines, systematic screening and monitoring of risk
factors, timetabled recall visits, information support for
the clinician, enhanced patient self-management, a
means of effective communication between all members
of the care team and audit information for the practice.
Since self-care for diabetes has been found to be subopti-
mal across a range of self-managed activities, particularly
for patients with depression, a collaborative care model
may be able to achieve better quality of care through the
case manager monitoring patient progress.10 11
Evaluation of a change in the way general practice
clinics look after patients requires complex intervention
methodology12 beyond single interventions such as the
introduction of a guideline with financial incentives.13
This methodology began with a search for potential
models of care (step I), and led to adopting the
University of Washington’s successful IMPACT model of
Collaborative Care for depression.14 15 In the exploratory
trial (step II), our pilot project16 adapted IMPACT by
training PNs as case managers. PNs were trained to
screen for depression using a patient self-report measure,
the nine-item Patient Health Questionnaire (PHQ-9),17
as part of comprehensive chronic disease management.
They were also trained to use a protocol for care manage-
ment based on the depression scores. The depression
screening and management were embedded in routine
visits for patients with diabetes or CHD. The pilot demon-
strated that it was feasible to detect, monitor and treat
depression in routine general practice alongside the
usual biophysical measures, and identified moderate-to-
severe depression in 34% of participants. The TrueBlue
study was a randomised cluster trial (step III) that built
on and extended the pilot. It investigated whether a col-
laborative care model (the intervention) is better than
usual care (the control) for the management of patients
with depression and T2DM, CHD or both in Australian
general practice. It was designed to fit into normal clinic
operations, making use of practice nurses and medical
software, and was able to be funded by existing Australian
Medicare rebates.
METHODS/DESIGN
Study design
The design and methodology of the study have been
described in detail elsewhere.18 The study started in 2009
and was undertaken in two phases. The first phase was a
cluster randomised intervention trial in which general
practices were randomly allocated to either an interven-
tion group, in which nurse-led collaborative care was
undertaken, or to a wait-list control group in which usual
care led by the general practitioner (GP) was continued.
At 6 months, the TrueBlue training was provided to the
control practices. The key aims of the first phase were to
determine whether participants with moderate-to-severe
depression in the intervention group showed at least a
five-point reduction from the baseline depression scores
after 6 months of intervention and whether this reduc-
tion was significantly better than in the control group.
A five-point reduction reflects a clinically relevant
change in individuals receiving depression treatment.19
The secondary outcome was to determine whether the
intervention also led to improvements in the patients’
physiological measures. The second phase followed the
intervention group for an additional 6 months to deter-
mine how the collaborative care model affected health
outcomes over a 12-month period.
Sample size
The sample size calculation was based on detecting a
50% reduction in depression score at the 0.05 signifi-
cance level with 80% power and a two-tailed test.
ARTICLE SUMMARY
Strengths and limitations of this study
▪ The TrueBlue model of collaborative care overcomes many of
the difficulties in implementing a guideline for the treatment of
comorbid depression.
▪ The study’s purpose-designed care plan gives patients and
their carers, allied health professionals, specialists and general
practitioners ready access to patient details, enabling them to
see at a glance where improved clinical care may be needed.
▪ Clinics were able to recover the costs of the collaborative care
through Australian Medicare rebates.
▪ The study could only be run in practices that had a practice
nurse on staff to carry out the intervention and had access to
clinical software capable of generating a disease registry from
which patients could be selected to participate in the trial.
▪ Differences between TrueBlue-practice and control-practice out-
comes may have been reduced by patients completing the
nine-item Patient Health Questionnaire (PHQ-9) depression
questionnaire and reading the project description, and by
general practitioners being made aware of individual PHQ-9
results so that they could take action where warranted.
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Detecting a 50% reduction is more stringent than
detecting a five-point reduction and provided some add-
itional buffering. Using depression scores from an
earlier study (a mean of 5.5 and an SD of 6.1),11 the cal-
culation indicated that 237 patients would be required
in each group. An intracluster correlation of 0.04 was
used (SK Lo, personal communication), with a recruit-
ment target of 50 patients per clinic. (Fifty patients were
chosen so that clinics could budget for a nurse’s time to
carry out the intervention with four patients each week
over the 3-month cycle of care.) To allow for difficulties
in recruitment, a 50% dropout was used. On the basis of
these, the study required 450 patients from nine clinics
in the intervention group and the same in the control
group.
Practice recruitment
Practices were identified in city and country areas on the
basis of having a PN to provide the collaborative care
and being able to identify eligible patients, those with
CHD or T2DM or both, from their registries; these were
invited to participate in the study until the 18 clinics
required by the sample-size calculation were recruited.
They were allocated by a random number generator to
either the intervention or control arm of the study. The
unit of randomisation was the clinic. Five practices
(three country, two city) in the intervention group and
six (two country, four city) in the control group com-
pleted the study. One country intervention clinic with-
drew while the first-visit data were being collected when
its TrueBlue-trained PN left the clinic, but some (n=13)
patients from it did complete the study and data were
collected from them. The study team was not able to
determine why the other clinics withdrew.
Patient selection
Eligible patients were sent a postal survey that included
a consent form which they were asked to complete and
return with the enclosed PHQ-9 questionnaire, a self-
report measure of depression.17 The PHQ-9 has nine
items, each scored from 0 (no problems) to 3 (problems
nearly every day). The sum of the scores of the nine
items will lie in one of five depression categories: none
(0–4), mild (5–9), moderate (10–14), moderately severe
(15–19) and severe (20–27). (While it is known that
responses to some of the PHQ-9 items may overlap with
diabetes symptoms,20 our pilot demonstrated that nurses
and patients preferred using the PHQ-9 because the
patient’s response to each of its items became the basis
for the problem-solving and goal-setting activities that
were part of TrueBlue.) Patients with scores of 5 or
above, indicating some form of depression, were invited
to participate in the study. A maximum of 50 patients
per practice were invited. Patients in residential care or
under 18 years of age were not eligible. Figure 1 pre-
sents the CONSORT diagram of the patient-recruitment
process.
Patient safety
Participation in the intervention included a series of
patient visits to their PN and usual GP every 3 months
over a 12-month period. Patients in the control group
continued with their ‘usual care’. The control clinics
were also provided with the PHQ-9 depression scores to
ensure patient safety during the trial. The protocol
required that PNs take action if severe depression was
recorded in the returned PHQ-9 or if the patient had
responded to the suicidal-ideation question (question 9)
on the questionnaire. This action was to be taken irre-
spective of whether the clinic was in the intervention or the
control group.
PN training
The PN training included a 2-day workshop to prepare
them for their enhanced roles in nurse-led collaborative
care. Topics in the workshop included identifying and
monitoring depression using the PHQ-9 questionnaire,
and quality of life responses using V.2 of the SF36 ques-
tionnaire.21 Patient goal setting and problem solving
were key components of the training with a particular
emphasis on behavioural techniques to achieve
improved mental health.22 The training also prepared
the PNs for their role as case managers including ensur-
ing that the Diabetes Australia and Australian National
Heart Foundation guidelines were being followed and
referrals were provided to appropriate services, such as
allied health and mental health professionals, through
discussion with the GPs.
Data collection
The research team developed a protocol-driven care-
plan template from which study data could be extracted
automatically and sent to the research team. The tem-
plate was designed to be a multipurpose document in
which the patient’s medical history, current medications,
allergies, biophysical and psychosocial measures, lifestyle
risks, personal goals and referrals were recorded. It was
designed to comply with the requirements to claim
Australian Medicare rebates for care planning and to
provide a checklist for ‘gold-standard’ care. A copy of
the care plan was provided to the patient as a written
record of their progress.
The care-plan template collected physical measures,
including body mass index, waist circumference, weight
and blood pressure and the latest pathology results,
including lipid profile, glycaemic control (glycosylated
haemoglobin, HbA1c) and renal function. Data also
included lifestyle risk factors, such as smoking, alcohol
consumption and level of physical activity, and depres-
sion score as measured by the PHQ-9 questionnaire.
Referrals to and attendance at exercise programmes and
with mental health workers were also recorded, along
with the patient’s own goals and possible barriers to
achieving these goals. The care-plan template was used
by the intervention-group clinics to acquire patient data
at three monthly intervals over a 12-month period.
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In the control group, the only complete dataset
recorded using our comprehensive protocol-driven care-
plan template was obtained after the 6 months of ‘usual
care’ when the TrueBlue training was offered to the
control clinics. No baseline or 3-month datasets were
acquired since the study was deliberately designed to
avoid changing the ‘usual care’ that would have other-
wise occurred by introducing our care-plan template.
The study was designed in this way to be run pragmatic-
ally in the context of the clinics’ normal activities. The
only baseline measure obtained was the depression
score. On completion of the study, we retrospectively
collected all the baseline data that the control clinics
routinely recorded in their electronic medical records in
order to have data for two time points, baseline and
6 months.
Trueblue collaborative care
As part of the TrueBlue model, patients were scheduled to
visit the practice every 3 months for a 45 min nurse consult
followed by a 15 min consult with their usual GP, in which
stepped care (psychotherapy or pharmacotherapy) was
offered if depression scores had not improved or had not
dropped below a value of 5. The PN used the care-plan
template and obtained current physical measures and
reviewed recent pathology results. PNs also reviewed life-
style risk factors. They readministered the PHQ-9 and
worked with the patient to identify possible barriers to
achieving their goals and discussed ways to overcome the
barriers. This information gathering phase of the consult-
ation was an opportunity to assist the patient with self-
management by discussing the available educational
resources, such as the library of fact sheets on aspects of
self-management of depression, and setting personal goals
for review at the next 3-monthly visit.
Statistical analysis
Participants in this study were clustered under clinics by
design. It is known that clinics are likely to be different
from each other and that ignoring the nested nature of
the data may lead to biased estimates of parameter SEs.
However, statistical techniques for correcting for the
effects of clustering tend to be overly severe and conser-
vative23 when a small number of higher level units
Figure 1 CONSORT flow diagram of the recruitment process.
4 Morgan MAJ, Coates MJ, Dunbar JA, et al. BMJ Open 2013;3:bmjopen2012002171. doi:10.1136/bmjopen-2012-002171
TrueBlue model of collaborative care
group.bmj.com on September 16, 2017 - Published by http://bmjopen.bmj.com/Downloaded from 
(clusters) are used, and therefore we tested whether the
clinics were in fact significantly different from each
other. Analysis of covariances (ANCOVAs)24 25 were used
to adjust for baseline values and to test the significance
of changes in depression scores between clinics after
6 months, using STATAV.11.1 for the statistical analyses.
Of the five clinics in the intervention (clinics 4, 5, 13,
15 and 17), only clinics 4 and 17 were significantly dif-
ferent from each other (F(1,76)=9.6, p<0.001). No other
comparisons were significant between intervention
clinics. Of the six clinics in the control group (clinics 1–
3, 6, 16 and 18), only clinics 6 and 18 were significantly
different from each other (F(1,78)=14.5, p<0.001). No
other comparisons were significant between control
clinics. Furthermore, the intracorrelation coefficient of
0.058 for the primary outcome suggests that only 6% of
the variance could be attributed to the clinic’s level.
Given this lack of difference between the clinics in each
arm coupled with the sample-size requirements for reli-
able multilevel modelling,26 we analysed our data at the
patient level.
In order to compare the effectiveness of the TrueBlue
care model to the usual-care control, ANCOVAs were
used to adjust for baseline values and test the signifi-
cance of changes in continuous variables between the
two groups after 6 months. A multilevel mixed-effects
logistic regression (STATA’s xtmelogit) was used to test
the significance of changes in the binary (categorical)
variables between the two groups after 6 months, with
time and group as the independent variables and with
random effects at the patient level. (We used the
mixed-effects logistic-regression model since the pairs of
observations over time are not independent, ie, observa-
tions at 6 months would be expected to be related to
the initial baseline observations.) Within each group,
changes between the two time points (baseline and
6-month visits) were tested using paired t tests for
the continuous variables and matched-case–control
McNemar χ2 tests for the binary variables.
The longer-term effects of the intervention were evalu-
ated over the 12-month period using multilevel
mixed-effects linear regression (STATA’s xtmixed) for
the continuous variables and multilevel mixed-effects
logistic regression (xtmelogit) for the binary variables.
All the 3-monthly data available in the intervention
group over the 12 months were used. Note that the
study design could not collect such ‘usual care’ data
from the control clinics since the data collection proto-
col was part of the intervention. In addition, TrueBlue
training was provided to these clinics at 6 months after
which they ceased to be a control.
Patients from the clinics who withdrew before or
during collection of first-visit data were excluded from
the analyses. (Data for the 13 patients from one of these
clinics who did complete the study have been included.)
Characteristics from available clinics were compared
between early dropouts and participating clinics and
addressed in terms of their possible impact on the
generalisability of the results. Missing 6-month data were
replaced with their baseline values using the ‘no
change’ formulation of intention-to-treat by assuming
that no change occurred between baseline and
6 months. The underlying assumptions of the statistical
tests used were assessed.
RESULTS
Demographics)
A total of 5401 invitations (3104 interventions and 2297
controls; see figure 1) were posted to patients with either
T2DM or CHD (or both) identified in the clinics’ regis-
ters. Approximately 30% (1057 interventions and 537
controls, including 39 additional patients invited in the
waiting room) of the invitations were returned with com-
pleted constant forms and PHQ-9 questionnaires. This
proportion is typical in studies of this type reported in
the literature. Of these, 34% (300 interventions and 229
controls) were eligible (a depression score or 5 or more)
and were invited to participate. However, 25% of these
(94 interventions and 36 controls) did not start when
their clinics withdrew before data collection began.
Of the 206 patients in the intervention who started
the study (figure 1), 17% (n=36) were forced to leave
when their clinics withdrew the study. A further 14%
(n=28) of patients withdrew as the study progressed,
with 4% leaving after 6 months, 5% after 9 months and
5% after the full year. Reasons included leaving the
area, going into residential care or becoming too ill to
continue, but no consistent pattern could be identified.
(The exact numbers for each reason are not known.) In
the control group, 24% (n=47) of the 194 patients who
agreed to participate had forgotten about the study by
the time the 6-month review was to be undertaken and
did not want to proceed.
Table 1 presents the characteristics of the patients in
both the intervention and control groups who started
the study. It shows that these characteristics were similar
across both groups. There were no significant differ-
ences in patient characteristics between the intervention
and control at baseline.
Phase 1: comparison of outcomes between the control
and intervention groups after 6 months
Table 2 presents the baseline and 6-month data for
markers used to monitor control of chronic disease for
both the intervention and control groups. While the
6-month depression scores for all 310 patients (164
interventions and 146 controls) were significantly lower
than those at baseline in both the intervention group
(10.7±0.7 reducing to 7.1±0.8, t(163)=8.38, p<0.001) and
the control group (11.6±0.9 reducing to 9.0±0.9, t(145)
=6.01, p<0.001), the ANCOVA, adjusting for the baseline
scores, showed that the improvement was significantly
better in the intervention group than in the control
group (F(1,309)=6.40, p=0.012). (The 95% confidence
ranges are indicated by the plus–minus sign.)
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Half of the patients had only mild depression at base-
line (PHQ-9 scores between 5 and 9). Because the
reported score for many of these patients may be due to
their diabetes rather than depression,20 the intervention
is unlikely to be able to change these scores. This is one
reason why Katon et al15 used a score of 10 or more as
an inclusion criterion in their study. Consequently, we
examined the change to baseline PHQ-9 scores for the
164 patients (81 interventions and 83 controls) with
moderate-to-severe depression (PHQ-9 scores of 10 or
more) at baseline. These patients showed significant
improvement, with the mean depression score in the
intervention group dropping by 5.7±1.3, from 14.4±1.1
down to 8.7±1.3 (t(80)=9.00, p<0.001), a clinically signifi-
cant change.19 The improvement in the intervention
group for these patients was significantly better than in
the control group (F(1,161)=4.02, p=0.047) where the
depression score dropped by 4.3±1.2, from 15.1±1.1
down to 10.8±1.4 (t(82)=6.88, p<0.001).
Except for the high-density lipoprotein (HDL) mea-
surements, there were no significant changes in biophys-
ical measures after 6 months in either group. Smoking
rates were low at baseline in the patients with established
cardiovascular risk factors. Recording of alcohol was sub-
optimal, although it was better than in other Australian
primary care surveys.27
The intervention group also showed a significantly
greater number of patients exercising, referred to and
attending an exercise programme, and referred to and
attending a mental health worker after 6 months of col-
laborative care. In the control group, there were no sig-
nificant changes observed after 6 months, except that
referrals to a mental health worker increased signifi-
cantly (p<0.001) from 9% to 21%, consistent with the
action being taken by the nurses as required by the
protocol. Neither group showed any significant
changes in the number of patients taking antidepressant
medication.
Phase 2: chronic disease outcomes over 12 months using
TrueBlue collaborative care
Table 3 presents data at baseline and 12 months for the
intervention group for markers used to monitor control
of existing diabetes and CHD. The improvement in
mental health observed after 6 months was maintained
at 12 months, with a significant reduction in the mean
depression score being maintained (10.7±0.7 to 6.6±0.7,
t(163)=9.92, p<0.001) and nearly 70% of patients having
lower depression scores than at baseline after 1 year.
Patients with moderate–to-severe depression at baseline
showed an even greater improvement after 12 months of
collaborative care, with the mean depression score drop-
ping by 6.4±1.2, from 14.4±0.8 to 8.0±1.2 (t(80)=10.41,
p<0.001). A significant improvement in the mean
SF36v2 composite mental-health and physical-health
scores, which was observed after 6 months, was also
maintained at 12 months.
Physiological measures showed a trend, although not
significant, to improvement in weight, systolic blood
pressure and HDL. Mean baseline lipids and HbA1c
were close to guideline targets. The 10-year cardiovascu-
lar disease (CVD) risk calculated with the Framingham
risk equations28 suggests a small but significant
(p=0.015) reduction in risk from 27.4% to 24.8% for
patients with only T2DM. (The Framingham risk equa-
tions cannot be used for those patients who have CHD.)
The most notable changes in lifestyle after 12 months
of the intervention were a significant increase in the
number of patients who reported taking regular exercise
or being referred to an exercise programme. Reported
Table 1 Patient characteristics at the baseline visits. There were no significant differences between the intervention and
control at baseline
Characteristics Intervention group (n=170) Control group (n=147)
Male (%)/female (%) 51.8%/48.2% 55.2%/44.8%
Age (year) 68.0±11.7 67.6±11.2
Aboriginal or Torres Strait Islander (%) 0.0% 0.7%
Diagnosis
Type 2 diabetes 37.6% 47.6%
CHD 45.3% 35.8%
Both 17.1% 16.6%
Body mass index (kg/m2) 31.4±6.0 (n=170) 30.8±6.0 (n=103)
Systolic blood pressure (mm Hg) 134.1±19.0 (n=169) 133.5±19.6 (n=112)
Total cholesterol (mmol/l) 4.21±0.94 (n=165) 4.41±1.06 (n=110)
Triglycerides (mmol/l) 1.73±0.88 (n=165) 1.92±1.37 (n=105)
LDL (mmol/l) 2.22±0.74 (n=159) 2.37±0.88 (n=89)
HDL (mmol/l) 1.23±0.36 (n=159) 1.18±0.33 (n=97)
HbA1c (mmol/l) 7.00±1.21 (n=94) 7.19±1.42 (n=69)
PHQ-9 score 10.7±4.7 (n=164) 11.6±5.5 (n=146)
PHQ-9 score range at baseline 5–24 5–27
CHD, coronary heart disease; HbA1c, glycosylated haemoglobin; HDL, high-density lipoprotein; LDL, low-density lipoprotein; PHQ-9,
nine-item Patient Health Questionnaire.
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Table 2 TrueBlue outcomes at 6 months in the intervention and control groups
Intervention Control
Between groupsn Baseline 6 months Within group* n Baseline 6 months Within group†
PHQ9 depression score 164 10.7±0.8 7.1±0.8 p<0.001 146 11.6±0.9 9.0±0.9 p<0.001 p=0.012
SF36v2 mental-health score‡ 71 37.2±3.4 41.1±3.4 p=0.034 Not recorded NS
SF36v2 physical-health score‡ 71 39.9±2.2 42.5±2.6 p=0.023 Not recorded NS
Body mass index (kg/m2) 162 31.3±1.0 31.2±1.0 NS 103 30.8±1.2 31.0±1.0 NS NS
Waist (cm) 161 104.7±2.4 105.0±2.4 NS 80 104.2±4.0 105.8±3.2 NS NS
Systolic blood pressure (mm Hg) 161 134.2±3.0 132.4±2.8 NS 112 133.5±3.8 131.2±3.4 NS NS
Total cholesterol (mmol/l) 158 4.21±0.16 4.22±0.14 NS 109 4.41±0.20 4.44±0.20 NS NS
LDL (mmol/l) 154 2.23±0.12 2.17±0.14 NS 86 2.37±0.18 2.29±0.20 NS NS
HDL (mmol/l) 154 1.23±0.06 1.29±0.06 p=0.023 93 1.17±0.06 1.27±0.08 p=0.011 NS
Triglycerides (mmol/l) 158 1.72±0.14 1.66±0.12 NS 104 1.84±0.22 1.75±0.18 NS NS
HbA1c (%)§ 89 6.97±0.24 6.90±0.26 NS 67 7.22±0.34 7.40±0.36 NS p=0.049
10- Year CVD risk¶ 61 26.9±3.2 26.1±3.2 NS 46 26.3±3.6 24.7±3.2 NS NS
Smoking 162 15 (9%) 13 (8%) NS 110 13 (12%) 13 (12%) NS NS
Alcohol 104 47 (45%) 51 (49%) NS 42 27 (64%) 27 (64%) NS NS
Exercises 30 min/day, 5 days/week 162 66 (41%) 97 (60%) p<0.001 75 22 (29%) 22 (29%) NS p<0.001
Referred to exercise programme 162 32 (20%) 58 (36%) p<0.001 111 15 (14%) 10 (9%) NS p<0.001
Attends exercise programme 162 12 (7%) 23 (14%) p=0.041 79 12 (15%) 9 (11%) NS NS
On antidepressant medication 162 27 (17%) 34 (21%) NS 113 31 (27%) 36 (32%) NS p=0.025
Referred to mental health worker 162 47 (29%) 58 (36%) p=0.022 114 10 (9%) 24 (21%) p<0.001 p<0.001
Attends mental health worker 162 10 (6%) 37 (23%) p<0.001 109 14 (13%) 11 (10%) NS p=0.044
The 95% confidence ranges are indicated by the±sign. Note that lower scores indicate improvement for all items except the SF36v2 and HDL results, where higher scores indicate improvement.
Unit of alcohol is 10 g of ethanol.
The values in brackets are the percentages of the total n.
*Significant difference between baseline and 6-month values within the intervention clinics.
†Significant difference between baseline and 6 months within the control clinics.
‡SF36v2 questionnaires were not collected by all clinics.
§HbA1c results were only available for patients with T2DM.
¶CVD risk could only be calculated for patients with T2DM only.
CVD, cardiovascular disease; HbA1c, glycosylated haemoglobin was measured only for patients with diabetes; HDL, high-density lipoprotein; LDL, low-density lipoprotein; NS, no significant
difference; PHQ9, nine-question Patient Health Questionnaire; SF36v2, V.2 of the Short Form 36-Question health survey; T2DM, type 2 diabetes.
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referrals and visits to a mental health worker and
numbers taking antidepressant medication were also sig-
nificantly greater at 12 months.
The TrueBlue protocol also included goal setting so
that patients could become more proactive in their own
care. An analysis of participant goals revealed that
two-thirds of the visits resulted in at least one behav-
ioural activation goal being set and, over the course of
the study, 86% of patients identified a behavioural activa-
tion goal.
Adherence to guidelines
Figure 2 shows the percentage of TrueBlue patients who
had psychosocial and biophysical checks undertaken as
recommended by the Australian National Heart
Foundation and Diabetes Australia guidelines, with the
corresponding percentages for usual care being taken
from a study of a large sample of Australian general
practices.27
DISCUSSION
Outcomes of phase 1
Depression scores were significantly lower at 6 months
for patients in the intervention group compared with
those in the control group, and the improvement was
clinically significant for patients with moderate-to-severe
depression,19 with patients moving one depression cat-
egory. Patients experienced increased nurse contact
time through the nurse consultations. They were pro-
vided with information about mental health and their
physical health through psychoeducation resources and
had their treatment intensified when required.
Modalities included behavioural activation, antidepres-
sant medication and referrals to mental health profes-
sionals and exercise programmes. Similar improvements
in depression scores and stepped-up care were observed
in the collaborative care model of Katon et al.15 The
reduction in depression scores observed in the control
group could be explained, in part, by control practices
being provided with each patient’s entry-level depression
score during the recruitment process as part of the
study’s safety protocol. Usual care could have been influ-
enced by drawing attention to comorbid depression15 as
the protocol required that PNs take action if severe
depression was recorded or if the patient had responded
to the suicidal-ideation question. Referrals to mental-
health workers by the control clinics had increased sig-
nificantly, consistent with the clinics taking action where
warranted. It is also known29 that recruiting interested
Table 3 TrueBlue outcomes at 12 months within the intervention clinics only
Intervention
n Baseline 12 Months Within group*
PHQ9 depression score 164 10.7±0.7 6.6±0.7 p<0.001
SF36v2 mental-health score† 70 36.0±3.2 41.3±2.8 p<0.001
SF36v2 physical-health score† 70 40.6±2.2 44.3±2.8 p<0.001
Body mass index (kg/m2) 142 31.4±1.0 31.1±1.0 p=0.006
Waist (cm) 141 105.0±2.4 105.2±2.6 NS
Systolic blood pressure (mm Hg) 141 135.2±3.2 130.2±3.0 p=0.016
Total cholesterol (mmol/l) 138 4.18±0.16 4.28±0.16 NS
LDL (mmol/l) 135 2.19±0.12 2.24±0.20 NS
HDL (mmol/l) 135 1.22±0.06 1.36±0.08 p<0.001
Triglycerides (mmol/l) 138 1.73±0.16 1.63±0.14 p=0.004
HbA1c (%)‡ 79 7.01±0.26 7.04±0.28 NS
10-Year CVD risk§ 55 27.4±3.4 24.9±3.6 p=0.015
Smoking 142 15 (11%) 11 (8%) NS
Alcohol 95 45 (47%) 47 (49%) NS
Exercises 30 min/day, 5 days/week 142 57 (40%) 83 (58%) p<0.001
Referred to exercise programme 142 26 (18%) 53 (37%) p<0.001
Attends exercise programme 142 10 (7%) 17 (12%) NS
On antidepressant medication 142 22 (15%) 33 (23%) p=0.001
Referred to mental health worker 142 40 (28%) 59 (42%) p<0.001
Attends mental health worker 142 8 (6%) 25 (18%) p<0.001
The 95% confidence ranges are indicated by the±sign. Lower scores indicate improvement for all items except the SF36v2 and HDL results,
where higher scores indicate improvement.
The values in brackets are the percentages of the total n.
Unit of alcohol is 10 g of ethanol.
*Significant difference between baseline and 12-month values.
†SF36v2 questionnaires were not collected by all clinics.
‡HbA1c results were only available for patients with T2DM.
§CVD risk could only be calculated for patients with T2DM only.
CVD, cardiovascular disease; HbA1c, glycosylated haemoglobin; HDL, high-density lipoprotein; LDL, low-density lipoprotein; NS, no
significant difference; PHQ9, nine-question Patient Health Questionnaire; SF36v2, V.2 of the Short Form 36-Question health survey;
T2DM, type 2 diabetes.
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patients (those who wanted to participate) from inter-
ested clinics (those that agreed to join) can affect the
representativeness of the study population. GPs with a
particular interest in the study may be more likely to
participate and manage their patients more effectively,
irrespective of whether they are in the control or inter-
vention arm. Consequently, a reduction in depression
scores in the control group was expected, but the struc-
tured TrueBlue model did produce a significantly better
reduction in depression. While the effect size may be
small (Cohen’s f=0.15), it is important to note that
TrueBlue was designed to be implemented easily within
general practices, with running costs funded by existing
Australian Medicare rebates, and to make better use of
their existing resources. These features mean that
TrueBlue could be easily applied to patients across
general practices at a population level, making the bene-
fits clinically important.
Outcomes of phase 2
The key clinical outcomes over a 12-month period in
the intervention group (table 3) were a sustained
improvement in mental health, demonstrated by
symptom severity score (PHQ-9 total score) and by the
patient’s function and subjective evaluation of mental
health (SF36 mental health composite score) and phys-
ical health (SF36 physical health composite score).
Regular physical exercise has been shown to be import-
ant for reducing depression.30 The self-reported exercise
rates showed significant improvement over the
12 months of collaborative care intervention. The bio-
physical measures reported in table 3 showed modest
improvements after 12 months and the Framingham risk
equations28 suggest a small but significant reduction in
the 10-year CVD risk for the T2DM patients. These
improvements were achieved despite the fact that we did
not specifically select patients whose physiological
parameters exceeded guidelines. Rather, our recruit-
ment process was selected from the practice’s disease
registry on the basis of only the presence of depression
and T2DM or CHD, and consequently, many patients
were already being treated to target on measures such
as cholesterol and HbA1c, leaving little room for
improvement.
Limitations
We were able to run TrueBlue only in practices that used
clinical software, which we used to generate a disease
registry from which participants could be selected, and
had a PN on staff. Clinics that chose to take part in the
study may not have been representative of wider general
practice. Operational limitations further reduced the
number of practices over the duration of the study.
Patient response rates to the mail-out (28%) may reflect
anxiety over the new model of care where the patient
discloses depression and visits the PN first rather than
only the GP. Usual care in the control clinics may have
been changed by patients completing the PHQ-9 and
reading the project description. GPs were made aware of
individual PHQ-9 results and took action where war-
ranted. GP awareness of these biophysical and lifestyle
risks may be expected to change clinical management.
By design, TrueBlue practices needed to incorporate all
research activities within the context of their busy
clinics, and so only research data that could be extracted
automatically were collected. The data dropout resulting
from these two factors contributed to the observed small
effect size. We were not able to obtain multiple data sets
at three monthly intervals over 12 months of ‘usual care’
because the act of inviting patients and measuring
depression scores and biophysical measures would in
itself change the nature of usual care. In addition, prac-
tices would not have been willing to join the study if
there was a chance of being randomly allocated to
12 months of being in such a control arm.29
Collaborative care
A recent UK study has shown the difficulties of dissemin-
ating a guideline without guidance on how to imple-
ment collaborative care. Organisational barriers
included GPs finding the PHQ-9 awkward to use, nurses
not feeling confident or competent due to lack of train-
ing and no guidance on stepped care.13 The TrueBlue
model of collaborative care overcame many of these dif-
ficulties. Its successful components were:9 31
▸ Use of evidence-based guidelines. The National Heart
Foundation and Diabetes Australia Guidelines deter-
mined the disease management targets and fre-
quency of monitoring.
▸ Systematic screening and monitoring of risk factors. Patients
attended three monthly visits in which a care plan
with its checklist was completed. By providing a com-
prehensive collation of all necessary information, this
document made clinical management by the patient’s
GP easier, quicker and more accurate.
Figure 2 Recording of checks recommended by the
National Heart Foundation and Diabetes Australia guidelines.
Data for ‘usual care’ were adapted from reference 27. No
usual-care data were available for exercise.
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▸ Timetabled recall visits. The date of the next appoint-
ment was set during each visit. PHQ-9 was
re-administered and, if improvement was insufficient,
stepped care was followed by initiating drug therapy or
increasing the dose or by referral to a mental-health
worker according to the guidelines.
▸ New or adjusted roles for team members. PNs took respon-
sibility for organising and monitoring the outcome of
referrals, goals and targets. They used a depression
questionnaire (the PHQ-9) to open a discussion with
patients about their depression symptoms.
▸ Information support for the clinician. GPs were provided
with the care plan by the PNs.
▸ Enhanced patient self-management. Patients received their
own copy of the care plan with personalised goals,
current measurements, targets and safety advice. A com-
ponent of each visit was to discuss and update their plan
and receive education material on depression.
▸ Identified case manager. PNs became case managers,
but the GP remained the key clinician.
▸ Means of effective communication between all members of the
care team. The care plan was designed to provide rele-
vant clinical information in a succinct format while
still being comprehensible to patients.
▸ Audit information for the practice. Deidentified data were
provided automatically through the care plan.
Applicability of TrueBlue
TrueBlue used existing clinical software and improved
the focus of the GP consultation by delegating some
tasks to the PN. Higher levels of adherence to
guideline-recommended checks were also reported for
TrueBlue. Patients and their carers, allied health profes-
sionals, specialists and GPs gained ready access to
patient details provided in TrueBlue’s care plan, enab-
ling them to see at a glance where improved clinical
care may be needed. The study achieved improved out-
comes with the potential for prevention of heart attack
and stroke through reduced 10-year CVD risk. The care
plan template also allowed the practice to collect high
quality audit data without taking up clinical time. While
it was not possible to obtain complete financial data
from the clinics specifically relating to the TrueBlue
visits, the data that are available suggest that clinics did
indeed cover their costs in implementing TrueBlue
through Australian Medicare rebates. The success of
TrueBlue and TeamCare15 demonstrates that collabora-
tive care is feasible in routine general practice in
Australia and the USA, and could lead to improved out-
comes for patients with depression and other chronic
diseases.7 32
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